世界のウェアラブルインジェクター市場2022年-2028年:治療別(糖尿病、心血管疾患、免疫腫瘍)、エンドユーザー別、種類別、技術別、地域別

【英語タイトル】Global Wearable Injectors Market Size, Share & Industry Trends Analysis Report By Therapy (Diabetes, Cardiovascular disease, Immuno-oncology), By End User, By Type, By Technology, By Regional Outlook and Forecast, 2022 – 2028

KBV Researchが出版した調査資料(KBV22JL096)・商品コード:KBV22JL096
・発行会社(調査会社):KBV Research
・発行日:2022年5月
・ページ数:255
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:アメリカ、カナダ、メキシコ、ロシア、ドイツ、イギリス、フランス、スペイン、イタリア、中国、日本、インド、韓国、シンガポール、マレーシア、ブラジル、アルゼンチン、UAE、サウジアラビア、南アフリカ共和国、ナイジェリア
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,600 ⇒換算¥532,800見積依頼/購入/質問フォーム
Site License(同一拠点内で共有可)USD4,320 ⇒換算¥639,360見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

KBVリサーチ社では、世界のウェアラブルインジェクター市場規模が2028年まで129億ドルに達っし、予測期間中、年平均9.2%成長率で上昇すると予想しています。本調査レポートでは、ウェアラブルインジェクターの世界市場について幅広く調査し、市場範囲・手法、市場動向、競争分析、治療別(糖尿病、心血管疾患、免疫腫瘍、その他)分析、エンドユーザー別(病院&クリニック、在宅医療)分析、種類別(オンボディインジェクター、オフボディインジェクター)分析、技術別(スプリング、モーター、ロータリーポンプ、バッテリー、その他)分析、地域別分析、企業情報などの項目を掲載しています。企業情報としては、Insulet Corporation、United Therapeutics Corporation、ATS Automation Tooling Systems, Inc.、Ypsomed AG、Amgen, Inc.、West Pharmaceutical Services, Inc.、Zealand Pharma A/S (Valeritas, Inc.)、Medtronic PLC、CeQur SA、Subcuject ApSなどが含まれています。
・市場範囲・手法
・市場動向
・競争分析
・世界のウェアラブルインジェクター市場規模:治療別(糖尿病、心血管疾患、免疫腫瘍、その他)
・世界のウェアラブルインジェクター市場規模:エンドユーザー別(病院&クリニック、在宅医療)
・世界のウェアラブルインジェクター市場規模:種類別(オンボディインジェクター、オフボディインジェクター)
・世界のウェアラブルインジェクター市場規模:技術別(スプリング、モーター、ロータリーポンプ、バッテリー、その他)
・世界のウェアラブルインジェクター市場規模:地域別(北米、ヨーロッパ、アジア太平洋、南米・中東・アフリカ)
・企業情報

The Global Wearable Injectors Market size is expected to reach $12.9 billion by 2028, rising at a market growth of 9.2% CAGR during the forecast period.
Wearable injectors (WIs) are drug delivery systems that anchor to the body and release significant amounts of medicine subcutaneously over time. Wearable injectors provide medications at predetermined intervals over a particular timeframe. Wearable injectors allow patients to self-inject medication, alleviating the strain on doctors and healthcare personnel. Wearable injectors are important in the treatment of diabetes and a variety of chronic conditions, including cancer, respiratory ailments, and arthritis. Because they do not require additional equipment or a competent person to give medications, wearable injectors are more affordable than IV infusions.
The presence of the growing healthcare industry has aided sales in the wearable injectors market. It is critical for individuals with chronic conditions to have appropriate treatment as well as dosage at regular intervals. Wearable injectors have evolved as a self-administered and self-scalable technology that can assist patients in ensuring that their medication dosage is taken on a regular basis. Wearable injectors have gained popularity due to the requirement to provide the correct volume of medical fluid. It is critical for medical practitioners and healthcare specialists to educate the public about the benefits of employing newer technology like wearable injectors and other gadgets. In the coming years, the increased occurrence of chronic conditions that mandate the utilization of seamless technologies would be a major driver of the market demand.
The rise in the prevalence of chronic conditions, the shift toward new drug delivery technologies, and improvements in wearable injector development are all factors driving market expansion. According to the Centers for Disease Control and Prevention (CDC), 129 million non-institutionalized civilian people were diagnosed with at least one chronic illness in 2018. Furthermore, as people’s concerns about immunological disease develop, the wearable injector industry would grow. Moreover, the rising need for effective, quick, and precise treatment outcomes has prompted the development of improved wearable injectors, moving the market forward.

COVID-19 Impact
The COVID-19 pandemic surged the demand for wearable injectors. In response to the COVID-19 outbreak, medical priorities have been reoriented across healthcare facilities, with treatment for COVID-19 patients taking priority. Wearable injectors offer a viable platform for closing the gap between in-clinic treatment and auto injectors. Wearable injectors addressed major loopholes in healthcare infrastructure as well as connected health services. As patients with cardiovascular, chronic pulmonary and neurological diseases begin to manage the long-term repercussions of the disease, an increase in chronic ailments resulting from COVID-19 morbidity may partially fuel expansion in the adoption of wearable injectors. To protect themselves from COVID-19 exposure at clinics, patients with chronic diseases are requesting a transition from clinic to at-home drug delivery.

Market Growth Factors
Rising consumer preference for home care solutions
The COVID-19 pandemic’s uncertainty has driven demand for various therapeutics as well as wearable drug delivery technologies. Healthcare systems around the world took steps to postpone treatments for diseases like cancer to prevent the spread of the infection and safeguard high-risk patients from infection. The hazards for individuals receiving care rose as the pandemic began. Hospitals, which serve the bulk of patients, also became high-risk areas during the epidemic. To address these issues and provide appropriate care to patients suffering from various ailments, a movement from hospital-based treatment to home-based care has occurred.

Rising demand for mAbs and biologics
Biologics and mAbs are mandated to be supplied via the parenteral route, due to which, an increasing focus on their usage to treat diseases like cardiovascular disease, rheumatoid arthritis, and cancer would create major development prospects for wearable injectors such as subcutaneous, intravenous, or intramuscular delivery. In addition, a significant number of biologics were in development in recent years, and the number of biologic pharmaceuticals in development continues to rise exponentially. mAb-based biotherapies currently account for a significant proportion of 100 medications.

Market Restraining Factors
Lack of favorable reimbursement policies
In the healthcare infrastructure of any nation, the government plays a crucial role in the development of assets. In addition, the government is also responsible for making various advanced healthcare devices accessible to people. However, there is a lack of favorable reimbursement policies for making wearable injectors accessible to people in several countries. Wearable injectors are not reimbursed in a number of underdeveloped nations. Wearable insulin pumps, for example, are not paid in several countries, and there are no precise rules for their use on prescription. Patients with Type 1 diabetes in numerous countries must pay for their insulin pumps as well as refills and supplies on their own. The absence of reimbursement has a direct impact on access to and acceptance of wearable injectors.

Therapy Outlook
Based on Therapy, the market is segmented into Diabetes, Cardiovascular disease, Immuno-oncology, and Others. In 2021, the Cardiovascular diseases segment witnessed a significant revenue share of the wearable injectors market. The increasing growth of the segment is attributed to the rising adoption of unhealthy lifestyles among people all over the world. CVDs (cardiovascular diseases) are a group of heart and blood vessel problems. Heart attacks and strokes are frequently sudden occurrences caused by a blockage that prohibits blood from reaching the heart or brain. A build-up of fatty plaques on the inner walls of the blood arteries that supply the heart or brain is the most common cause. Strokes are caused by blood clots or bleeding from a blood artery in the brain.

End User Outlook
Based on End User, the market is segmented into Hospitals & Clinics and Home healthcare setting. In 2021, the hospitals & clinics segment held the highest revenue share of the wearable injectors market. The growth of the segment is surging due to the rising disposable income of the people. With a surge in the disposable income of people all over the world, the demand for enhanced and efficient treatment for diseases and disorders is also rising. Moreover, hospitals and clinics offer more precision during the treatment, which is propelling the growth of the segment.

Type Outlook
Based on Type, the market is segmented into On-body Injector and Off-body Injector. In 2021, the off-body segment garnered a significant revenue share of the wearable injectors market. The increasing growth of the segment is attributed to the fact that off-body wearables can dispense significant amounts of very high volumes of viscous medicines. Due to this factor, market players are witnessing significant demand for off-body wearable injectors. Hence, the growth of the segment is estimated to bolster.

Technology Outlook
Based on Technology, the market is segmented into Spring Based, Motor Based, Rotary pump, Expanding battery, and others. In 2021, the Spring Based technology sector acquired the largest share. The increased demand for adhesive patches, which are user-friendly and allow patients to correctly give the appropriate medicine subcutaneously can be attributable to the rapidly rising growth of this segment.

Regional Outlook
Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. In 2021, North America accounted for the largest revenue share of the wearable injectors market. The increased frequency of chronic and lifestyle-related disorders, as well as the availability of advanced healthcare infrastructure across the region, account for the increasing growth of the regional market. The regional countries are early adopters of various latest and advanced technologies, due to which, the adoption of wearable injectors is estimated to rise in the region in the forecast period.
The major strategies followed by the market participants are Partnerships. Based on the Analysis presented in the Cardinal matrix; Medtronic PLC and Amgen, Inc. are the forerunners in the Wearable Injectors Market. Companies such as Insulet Corporation, United Therapeutics Corporation, Subcuject ApS are some of the key innovators in the Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Insulet Corporation, United Therapeutics Corporation, ATS Automation Tooling Systems, Inc., Ypsomed AG, Amgen, Inc., West Pharmaceutical Services, Inc., Zealand Pharma A/S (Valeritas, Inc.), Medtronic PLC, CeQur SA, and Subcuject ApS.

Recent Strategy Deployed in Wearable Injectors Market
Partnerships, Collaborations and Agreements
Apr-2022: West Pharmaceutical Services teamed up with Pneuma Systems, a medical technology company. Following this collaboration, Pneuma would deliver a novel closed-loop fluid flow control platform to West Pharmaceutical Services to aid in the development of drug delivery solutions. In addition, West Pharmaceutical Services would offer financial and technical support along with access to the developing West Digital Platform to Pneuma to accelerate the transmission of data along with other information.
Jan-2022: West Pharmaceutical Services teamed up with Corning Incorporated, a leader in innovating materials science. Through this collaboration, West Pharmaceutical Services would help Corning in expanding its Valor Glass technology in order to enable injectable drug packaging and delivery systems for the pharmaceutical sector with the purpose of enhancing patient safety as well as expanding access to life-saving treatments.
Feb-2021: Subcuject entered into collaboration with Phillips-Medisize, a Molex company. Under this collaboration, the companies aimed to introduce a ground-breaking wearable bolus injector across the market. In addition, the companies would avail osmosis-On-Body Delivery System technology.
Nov-2020: Ypsomed collaborated with SCHOTT and Lonza. With this collaboration, the companies aimed to develop a comprehensive solution for wearable patch injectors subcutaneous self-injection of big volumes of fluid formulations.
Feb-2020: Insulet partnered with Abbott, a multinational medical devices and healthcare company. Following this partnership, the companies would incorporate Insulet’s Omnipod Horizon with Abbott’s world-leading1 glucose-sensing technology in order to provide customized automated insulin delivery and care for diabetic people.

Product Launches and Product Expansions
Apr-2021: Medtronic introduced the Medtronic Extended infusion set. The new Extended infusion set is the first and only infusion set across the market that can be worn for more than 7 days, unlike other infusion sets that can be worn up to 2-3 days.
Feb-2021: United Therapeutics rolled out Remunity Pump for Remodulin. The new product aimed to help pulmonary arterial hypertension patients. In addition, the new product is a small and discreet pump that provides Remodulin in prefilled cassettes delivered directly to patients in order to offer major enhancements over prevailing subcutaneous pumps.

Acquisitions and Mergers
Apr-2021: Amgen took over Five Prime Therapeutics, a clinical-stage biotechnology business. Through this acquisition, the company aimed to integrate Five Prime’s offerings into its oncology portfolio in order to strengthen its vision for international expansion and further pipeline programs.
Aug-2020: Medtronic acquired Companion Medical, a med-tech company in San Diego. Through this acquisition, the company aimed to complement its strategy of streamlining diabetes management along with improving outcomes through the optimization of dosing decisions for a large number of people utilizing multiple injections daily.

Approvals and Trials
Jan-2022: Insulet received the US FDA approval for its Omnipod 5, an automated insulin delivery system. With this approval, the company aimed to integrate Omnipod 5 with Dexcom’s G6 continuous glucose monitoring system in order to introduce the first tubeless wearable automated insulin delivery system. Moreover, with this product, patients would be able to leverage a dedicated handheld controller or smartphone in order to control the system

Scope of the Study
Market Segments covered in the Report:

By Therapy
• Diabetes
• Cardiovascular disease
• Immuno-oncology
• Others

By End User
• Hospitals & Clinics
• Home healthcare setting

By Type
• On-body Injector
• Off-body Injector

By Technology
• Spring Based
• Motor Based
• Rotary pump
• Expanding battery
• Others

By Geography
• North America
o US
o Canada
o Mexico
o Rest of North America
• Europe
o Germany
o UK
o France
o Russia
o Spain
o Italy
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Singapore
o Malaysia
o Rest of Asia Pacific
• LAMEA
o Brazil
o Argentina
o UAE
o Saudi Arabia
o South Africa
o Nigeria
o Rest of LAMEA

Companies Profiled
• Insulet Corporation
• United Therapeutics Corporation
• ATS Automation Tooling Systems, Inc.
• Ypsomed AG
• Amgen, Inc.
• West Pharmaceutical Services, Inc.
• Zealand Pharma A/S (Valeritas, Inc.)
• Medtronic PLC
• CeQur SA
• Subcuject ApS

Unique Offerings from KBV Research
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

❖ レポートの目次 ❖

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Wearable Injectors Market, by Therapy
1.4.2 Global Wearable Injectors Market, by End User
1.4.3 Global Wearable Injectors Market, by Type
1.4.4 Global Wearable Injectors Market, by Technology
1.4.5 Global Wearable Injectors Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis – Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.2.5 Business Expansions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2018,Apr – 2022, Apr) Leading Players
Chapter 4. Global Wearable Injectors Market by Therapy
4.1 Global Diabetes Market by Region
4.2 Global Cardiovascular disease Market by Region
4.3 Global Immuno-oncology Market by Region
4.4 Global Others Market by Region
Chapter 5. Global Wearable Injectors Market by End User
5.1 Global Hospitals & Clinics Market by Region
5.2 Global Home healthcare setting Market by Region
Chapter 6. Global Wearable Injectors Market by Type
6.1 Global On-body Injector Market by Region
6.2 Global Off-body Injector Market by Region
Chapter 7. Global Wearable Injectors Market by Technology
7.1 Global Spring Based Market by Region
7.2 Global Motor Based Market by Region
7.3 Global Rotary pump Market by Region
7.4 Global Expanding battery Market by Region
7.5 Global Others Market by Region
Chapter 8. Global Wearable Injectors Market by Region
8.1 North America Wearable Injectors Market
8.1.1 North America Wearable Injectors Market by Therapy
8.1.1.1 North America Diabetes Market by Country
8.1.1.2 North America Cardiovascular disease Market by Country
8.1.1.3 North America Immuno-oncology Market by Country
8.1.1.4 North America Others Market by Country
8.1.2 North America Wearable Injectors Market by End User
8.1.2.1 North America Hospitals & Clinics Market by Country
8.1.2.2 North America Home healthcare setting Market by Country
8.1.3 North America Wearable Injectors Market by Type
8.1.3.1 North America On-body Injector Market by Country
8.1.3.2 North America Off-body Injector Market by Country
8.1.4 North America Wearable Injectors Market by Technology
8.1.4.1 North America Spring Based Market by Country
8.1.4.2 North America Motor Based Market by Country
8.1.4.3 North America Rotary pump Market by Country
8.1.4.4 North America Expanding battery Market by Country
8.1.4.5 North America Others Market by Country
8.1.5 North America Wearable Injectors Market by Country
8.1.5.1 US Wearable Injectors Market
8.1.5.1.1 US Wearable Injectors Market by Therapy
8.1.5.1.2 US Wearable Injectors Market by End User
8.1.5.1.3 US Wearable Injectors Market by Type
8.1.5.1.4 US Wearable Injectors Market by Technology
8.1.5.2 Canada Wearable Injectors Market
8.1.5.2.1 Canada Wearable Injectors Market by Therapy
8.1.5.2.2 Canada Wearable Injectors Market by End User
8.1.5.2.3 Canada Wearable Injectors Market by Type
8.1.5.2.4 Canada Wearable Injectors Market by Technology
8.1.5.3 Mexico Wearable Injectors Market
8.1.5.3.1 Mexico Wearable Injectors Market by Therapy
8.1.5.3.2 Mexico Wearable Injectors Market by End User
8.1.5.3.3 Mexico Wearable Injectors Market by Type
8.1.5.3.4 Mexico Wearable Injectors Market by Technology
8.1.5.4 Rest of North America Wearable Injectors Market
8.1.5.4.1 Rest of North America Wearable Injectors Market by Therapy
8.1.5.4.2 Rest of North America Wearable Injectors Market by End User
8.1.5.4.3 Rest of North America Wearable Injectors Market by Type
8.1.5.4.4 Rest of North America Wearable Injectors Market by Technology
8.2 Europe Wearable Injectors Market
8.2.1 Europe Wearable Injectors Market by Therapy
8.2.1.1 Europe Diabetes Market by Country
8.2.1.2 Europe Cardiovascular disease Market by Country
8.2.1.3 Europe Immuno-oncology Market by Country
8.2.1.4 Europe Others Market by Country
8.2.2 Europe Wearable Injectors Market by End User
8.2.2.1 Europe Hospitals & Clinics Market by Country
8.2.2.2 Europe Home healthcare setting Market by Country
8.2.3 Europe Wearable Injectors Market by Type
8.2.3.1 Europe On-body Injector Market by Country
8.2.3.2 Europe Off-body Injector Market by Country
8.2.4 Europe Wearable Injectors Market by Technology
8.2.4.1 Europe Spring Based Market by Country
8.2.4.2 Europe Motor Based Market by Country
8.2.4.3 Europe Rotary pump Market by Country
8.2.4.4 Europe Expanding battery Market by Country
8.2.4.5 Europe Others Market by Country
8.2.5 Europe Wearable Injectors Market by Country
8.2.5.1 Germany Wearable Injectors Market
8.2.5.1.1 Germany Wearable Injectors Market by Therapy
8.2.5.1.2 Germany Wearable Injectors Market by End User
8.2.5.1.3 Germany Wearable Injectors Market by Type
8.2.5.1.4 Germany Wearable Injectors Market by Technology
8.2.5.2 UK Wearable Injectors Market
8.2.5.2.1 UK Wearable Injectors Market by Therapy
8.2.5.2.2 UK Wearable Injectors Market by End User
8.2.5.2.3 UK Wearable Injectors Market by Type
8.2.5.2.4 UK Wearable Injectors Market by Technology
8.2.5.3 France Wearable Injectors Market
8.2.5.3.1 France Wearable Injectors Market by Therapy
8.2.5.3.2 France Wearable Injectors Market by End User
8.2.5.3.3 France Wearable Injectors Market by Type
8.2.5.3.4 France Wearable Injectors Market by Technology
8.2.5.4 Russia Wearable Injectors Market
8.2.5.4.1 Russia Wearable Injectors Market by Therapy
8.2.5.4.2 Russia Wearable Injectors Market by End User
8.2.5.4.3 Russia Wearable Injectors Market by Type
8.2.5.4.4 Russia Wearable Injectors Market by Technology
8.2.5.5 Spain Wearable Injectors Market
8.2.5.5.1 Spain Wearable Injectors Market by Therapy
8.2.5.5.2 Spain Wearable Injectors Market by End User
8.2.5.5.3 Spain Wearable Injectors Market by Type
8.2.5.5.4 Spain Wearable Injectors Market by Technology
8.2.5.6 Italy Wearable Injectors Market
8.2.5.6.1 Italy Wearable Injectors Market by Therapy
8.2.5.6.2 Italy Wearable Injectors Market by End User
8.2.5.6.3 Italy Wearable Injectors Market by Type
8.2.5.6.4 Italy Wearable Injectors Market by Technology
8.2.5.7 Rest of Europe Wearable Injectors Market
8.2.5.7.1 Rest of Europe Wearable Injectors Market by Therapy
8.2.5.7.2 Rest of Europe Wearable Injectors Market by End User
8.2.5.7.3 Rest of Europe Wearable Injectors Market by Type
8.2.5.7.4 Rest of Europe Wearable Injectors Market by Technology
8.3 Asia Pacific Wearable Injectors Market
8.3.1 Asia Pacific Wearable Injectors Market by Therapy
8.3.1.1 Asia Pacific Diabetes Market by Country
8.3.1.2 Asia Pacific Cardiovascular disease Market by Country
8.3.1.3 Asia Pacific Immuno-oncology Market by Country
8.3.1.4 Asia Pacific Others Market by Country
8.3.2 Asia Pacific Wearable Injectors Market by End User
8.3.2.1 Asia Pacific Hospitals & Clinics Market by Country
8.3.2.2 Asia Pacific Home healthcare setting Market by Country
8.3.3 Asia Pacific Wearable Injectors Market by Type
8.3.3.1 Asia Pacific On-body Injector Market by Country
8.3.3.2 Asia Pacific Off-body Injector Market by Country
8.3.4 Asia Pacific Wearable Injectors Market by Technology
8.3.4.1 Asia Pacific Spring Based Market by Country
8.3.4.2 Asia Pacific Motor Based Market by Country
8.3.4.3 Asia Pacific Rotary pump Market by Country
8.3.4.4 Asia Pacific Expanding battery Market by Country
8.3.4.5 Asia Pacific Others Market by Country
8.3.5 Asia Pacific Wearable Injectors Market by Country
8.3.5.1 China Wearable Injectors Market
8.3.5.1.1 China Wearable Injectors Market by Therapy
8.3.5.1.2 China Wearable Injectors Market by End User
8.3.5.1.3 China Wearable Injectors Market by Type
8.3.5.1.4 China Wearable Injectors Market by Technology
8.3.5.2 Japan Wearable Injectors Market
8.3.5.2.1 Japan Wearable Injectors Market by Therapy
8.3.5.2.2 Japan Wearable Injectors Market by End User
8.3.5.2.3 Japan Wearable Injectors Market by Type
8.3.5.2.4 Japan Wearable Injectors Market by Technology
8.3.5.3 India Wearable Injectors Market
8.3.5.3.1 India Wearable Injectors Market by Therapy
8.3.5.3.2 India Wearable Injectors Market by End User
8.3.5.3.3 India Wearable Injectors Market by Type
8.3.5.3.4 India Wearable Injectors Market by Technology
8.3.5.4 South Korea Wearable Injectors Market
8.3.5.4.1 South Korea Wearable Injectors Market by Therapy
8.3.5.4.2 South Korea Wearable Injectors Market by End User
8.3.5.4.3 South Korea Wearable Injectors Market by Type
8.3.5.4.4 South Korea Wearable Injectors Market by Technology
8.3.5.5 Singapore Wearable Injectors Market
8.3.5.5.1 Singapore Wearable Injectors Market by Therapy
8.3.5.5.2 Singapore Wearable Injectors Market by End User
8.3.5.5.3 Singapore Wearable Injectors Market by Type
8.3.5.5.4 Singapore Wearable Injectors Market by Technology
8.3.5.6 Malaysia Wearable Injectors Market
8.3.5.6.1 Malaysia Wearable Injectors Market by Therapy
8.3.5.6.2 Malaysia Wearable Injectors Market by End User
8.3.5.6.3 Malaysia Wearable Injectors Market by Type
8.3.5.6.4 Malaysia Wearable Injectors Market by Technology
8.3.5.7 Rest of Asia Pacific Wearable Injectors Market
8.3.5.7.1 Rest of Asia Pacific Wearable Injectors Market by Therapy
8.3.5.7.2 Rest of Asia Pacific Wearable Injectors Market by End User
8.3.5.7.3 Rest of Asia Pacific Wearable Injectors Market by Type
8.3.5.7.4 Rest of Asia Pacific Wearable Injectors Market by Technology
8.4 LAMEA Wearable Injectors Market
8.4.1 LAMEA Wearable Injectors Market by Therapy
8.4.1.1 LAMEA Diabetes Market by Country
8.4.1.2 LAMEA Cardiovascular disease Market by Country
8.4.1.3 LAMEA Immuno-oncology Market by Country
8.4.1.4 LAMEA Others Market by Country
8.4.2 LAMEA Wearable Injectors Market by End User
8.4.2.1 LAMEA Hospitals & Clinics Market by Country
8.4.2.2 LAMEA Home healthcare setting Market by Country
8.4.3 LAMEA Wearable Injectors Market by Type
8.4.3.1 LAMEA On-body Injector Market by Country
8.4.3.2 LAMEA Off-body Injector Market by Country
8.4.4 LAMEA Wearable Injectors Market by Technology
8.4.4.1 LAMEA Spring Based Market by Country
8.4.4.2 LAMEA Motor Based Market by Country
8.4.4.3 LAMEA Rotary pump Market by Country
8.4.4.4 LAMEA Expanding battery Market by Country
8.4.4.5 LAMEA Others Market by Country
8.4.5 LAMEA Wearable Injectors Market by Country
8.4.5.1 Brazil Wearable Injectors Market
8.4.5.1.1 Brazil Wearable Injectors Market by Therapy
8.4.5.1.2 Brazil Wearable Injectors Market by End User
8.4.5.1.3 Brazil Wearable Injectors Market by Type
8.4.5.1.4 Brazil Wearable Injectors Market by Technology
8.4.5.2 Argentina Wearable Injectors Market
8.4.5.2.1 Argentina Wearable Injectors Market by Therapy
8.4.5.2.2 Argentina Wearable Injectors Market by End User
8.4.5.2.3 Argentina Wearable Injectors Market by Type
8.4.5.2.4 Argentina Wearable Injectors Market by Technology
8.4.5.3 UAE Wearable Injectors Market
8.4.5.3.1 UAE Wearable Injectors Market by Therapy
8.4.5.3.2 UAE Wearable Injectors Market by End User
8.4.5.3.3 UAE Wearable Injectors Market by Type
8.4.5.3.4 UAE Wearable Injectors Market by Technology
8.4.5.4 Saudi Arabia Wearable Injectors Market
8.4.5.4.1 Saudi Arabia Wearable Injectors Market by Therapy
8.4.5.4.2 Saudi Arabia Wearable Injectors Market by End User
8.4.5.4.3 Saudi Arabia Wearable Injectors Market by Type
8.4.5.4.4 Saudi Arabia Wearable Injectors Market by Technology
8.4.5.5 South Africa Wearable Injectors Market
8.4.5.5.1 South Africa Wearable Injectors Market by Therapy
8.4.5.5.2 South Africa Wearable Injectors Market by End User
8.4.5.5.3 South Africa Wearable Injectors Market by Type
8.4.5.5.4 South Africa Wearable Injectors Market by Technology
8.4.5.6 Nigeria Wearable Injectors Market
8.4.5.6.1 Nigeria Wearable Injectors Market by Therapy
8.4.5.6.2 Nigeria Wearable Injectors Market by End User
8.4.5.6.3 Nigeria Wearable Injectors Market by Type
8.4.5.6.4 Nigeria Wearable Injectors Market by Technology
8.4.5.7 Rest of LAMEA Wearable Injectors Market
8.4.5.7.1 Rest of LAMEA Wearable Injectors Market by Therapy
8.4.5.7.2 Rest of LAMEA Wearable Injectors Market by End User
8.4.5.7.3 Rest of LAMEA Wearable Injectors Market by Type
8.4.5.7.4 Rest of LAMEA Wearable Injectors Market by Technology
Chapter 9. Company Profiles
9.1 Insulet Corporation
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research & Development Expenses
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.5.2 Approvals anf Trials:
9.2 United Therapeutics Corporation
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Product Launches and Product Expansions:
9.2.5.2 Acquisition and Mergers:
9.3 ATS Automation Tooling Systems, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Regional Analysis
9.4 Ypsomed AG
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Recent Strategies and Developments:
9.4.4.1 Partnerships, Collaborations, and Agreements:
9.4.4.2 Business Expansions:
9.5 Amgen, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Regional Analysis
9.5.5 Recent Strategies and Developments:
9.5.5.1 Acquisitions and Mergers:
9.6 West Pharmaceutical Services, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.6.4 Research & Development Expense
9.6.5 Recent Strategies and Developments:
9.6.5.1 Partnerships, Collaborations and Agreements:
9.6.5.2 Product Launches and Product Expansions:
9.7 Zealand Pharma A/S (Valeritas, Inc.)
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Research & Development Expenses
9.7.4 Recent strategies and developments:
9.7.4.1 Partnerships, Collaborations and Agreements:
9.8 Medtronic PLC
9.8.1 Company overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Product Launches and Product Expansions:
9.8.5.2 Acquisition and Mergers:
9.9 CeQur SA
9.9.1 Company Overview
9.9.2 Recent strategies and developments:
9.9.2.1 Acquisition and Mergers:
9.10. Subcuject ApS
9.10.1 Company Overview
9.10.2 Recent strategies and developments:
9.10.2.1 Partnerships, Collaborations, and Agreements:



★調査レポート[世界のウェアラブルインジェクター市場2022年-2028年:治療別(糖尿病、心血管疾患、免疫腫瘍)、エンドユーザー別、種類別、技術別、地域別] (コード:KBV22JL096)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のウェアラブルインジェクター市場2022年-2028年:治療別(糖尿病、心血管疾患、免疫腫瘍)、エンドユーザー別、種類別、技術別、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆